Fortress Biotech (FBIO) EBIT: 2013-2025
Historic EBIT for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to -$6.8 million.
- Fortress Biotech's EBIT rose 69.17% to -$6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$89.4 million, marking a year-over-year increase of 15.68%. This contributed to the annual value of -$110.4 million for FY2024, which is 22.46% up from last year.
- As of Q3 2025, Fortress Biotech's EBIT stood at -$6.8 million, which was up 81.33% from -$36.5 million recorded in Q2 2025.
- Fortress Biotech's 5-year EBIT high stood at -$6.8 million for Q3 2025, and its period low was -$62.0 million during Q4 2021.
- Moreover, its 3-year median value for EBIT was -$23.8 million (2024), whereas its average is -$28.9 million.
- In the last 5 years, Fortress Biotech's EBIT tumbled by 155.12% in 2021 and then spiked by 72.88% in 2023.
- Quarterly analysis of 5 years shows Fortress Biotech's EBIT stood at -$62.0 million in 2021, then climbed by 11.88% to -$54.6 million in 2022, then skyrocketed by 64.10% to -$19.6 million in 2023, then dropped by 21.52% to -$23.8 million in 2024, then spiked by 69.17% to -$6.8 million in 2025.
- Its last three reported values are -$6.8 million in Q3 2025, -$36.5 million for Q2 2025, and -$22.3 million during Q1 2025.